Abstract
Dysregulated leukocyte recruitment is believed to be a key contributor to various acute and chronic inflammatory disorders which can lead to serious pathological consequences. Chemokines are small molecular weight proteins that have been shown to be imperative in the direction of leukocytes to the sites of inflammation. In humans, several of these chemokines (CXCL8 and CXCL1) are elevated in inflammatory disorders such as asthma, arthritis, and chronic obstructive pulmonary disease (COPD). These chemokines modulate their downstream effects thru G-protein coupled receptors, such as CXCR2, making the identification of small-molecule antagonists of this receptor attractive towards developing novel therapies to treat inflammatory conditions. Since the first report of a CXCR2 receptor antagonist in 1998, there has been a considerable effort conducted mainly in the pharmaceutical industry to identify novel classes of CXCR2 receptor antagonists. Over a dozen distinct classes of CXCR2 receptor antagonists have been reported in the literature to date with a number of these compounds having reached mid-stage clinical trials. This review will provide a broad overview the medicinal chemistry efforts over the past 15 years towards the identification of CXCR2 receptor antagonists. The discussion will focus upon the early preclinical space covering the structure activity relationships (SAR), pharmacology, as well in preclinical in vivo evaluation for the different series of CXCR2 receptor antagonists. In addition, the available clinical data for the most advanced compounds in the clinic will be discussed and along with a perspective of the area moving forward.
Keywords: Chemokine, COPD, CXCR2, CXCR2 receptor antagonist, Gro-α (CXCL1), Interleukin-8 (IL-8 or CXCL8), medicinal chemistry.
Current Topics in Medicinal Chemistry
Title:CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Volume: 14 Issue: 13
Author(s): Michael P. Dwyer and Younong Yu
Affiliation:
Keywords: Chemokine, COPD, CXCR2, CXCR2 receptor antagonist, Gro-α (CXCL1), Interleukin-8 (IL-8 or CXCL8), medicinal chemistry.
Abstract: Dysregulated leukocyte recruitment is believed to be a key contributor to various acute and chronic inflammatory disorders which can lead to serious pathological consequences. Chemokines are small molecular weight proteins that have been shown to be imperative in the direction of leukocytes to the sites of inflammation. In humans, several of these chemokines (CXCL8 and CXCL1) are elevated in inflammatory disorders such as asthma, arthritis, and chronic obstructive pulmonary disease (COPD). These chemokines modulate their downstream effects thru G-protein coupled receptors, such as CXCR2, making the identification of small-molecule antagonists of this receptor attractive towards developing novel therapies to treat inflammatory conditions. Since the first report of a CXCR2 receptor antagonist in 1998, there has been a considerable effort conducted mainly in the pharmaceutical industry to identify novel classes of CXCR2 receptor antagonists. Over a dozen distinct classes of CXCR2 receptor antagonists have been reported in the literature to date with a number of these compounds having reached mid-stage clinical trials. This review will provide a broad overview the medicinal chemistry efforts over the past 15 years towards the identification of CXCR2 receptor antagonists. The discussion will focus upon the early preclinical space covering the structure activity relationships (SAR), pharmacology, as well in preclinical in vivo evaluation for the different series of CXCR2 receptor antagonists. In addition, the available clinical data for the most advanced compounds in the clinic will be discussed and along with a perspective of the area moving forward.
Export Options
About this article
Cite this article as:
Dwyer P. Michael and Yu Younong, CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective, Current Topics in Medicinal Chemistry 2014; 14 (13) . https://dx.doi.org/10.2174/1568026614666140827144615
DOI https://dx.doi.org/10.2174/1568026614666140827144615 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Recent Advances in the Chemistry of Phthalimide Analogues and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Treating Neonatal Brain Injury - Promise and Inherent Research Challenges
Recent Patents on Inflammation & Allergy Drug Discovery The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing- Remitting Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Keeping the Balance Between Proliferation and Differentiation:The Primary Cilium
Current Genomics Pseudomonas aeruginosa -Eukaryotic Cell Crosstalk: Mediators, Mechanisms and Implications for the Antimicrobial Therapy
Current Organic Chemistry Paediatric Respiratory Diseases: From Clinical Experience to Literature Review
Current Respiratory Medicine Reviews Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Current Medicinal Chemistry Cytokine Expression Profile in Aqueous Humor and Sera of Patients with Acute Anterior Uveitis
Current Molecular Medicine Atopic Dermatitis in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Recent Patents of Complementary and Alternative Medicine for Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism An Overview on Sources, Biosynthesis and Bioactivities of Osthole: A Potential Bioactive Compound
Current Bioactive Compounds Micropropagation: A Tool for the Production of High Quality Plant-based Medicines
Current Pharmaceutical Biotechnology Silent Airflow Obstruction and Air Trapping on Discharge in Children Hospitalized with Asthma
Current Respiratory Medicine Reviews The Possible Role of Pathogenic and Non-Pathogenic Bacteria in Initiation and Exacerbation of Celiac Disease; A Comprehensive Review
Current Pharmaceutical Biotechnology Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued)